Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$101.60 USD

101.60
4,907,837

-0.28 (-0.28%)

Updated Nov 4, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks Investment Ideas feature highlights: Palantir, Morgan Stanley, Merch, Paypal and Meta Platforms

by Zacks Equity Research

Palantir, Morgan Stanley, Merch, Paypal and Meta Platforms are part of the Zacks Investment Ideas article.

Andrew Rocco headshot

Palantir: A Bet on Geopolitical Turmoil & Government Spending

by Andrew Rocco

Palantir is one of the best growth stories on Wall Street. The company should be a big beneficiary of rising geopolitical tensions and rampant government spending.

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B

by Zacks Equity Research

Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates

by Kinjel Shah

Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Are You Looking for a High-Growth Dividend Stock?

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash

by Zacks Equity Research

Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.

Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View

by Zacks Equity Research

Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.

Case-Shiller Home Prices Tick in Higher

by Zacks Equity Research

Case-Shiller Home Prices Tick in Higher.

Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View

by Zacks Equity Research

Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.

Mark Vickery headshot

Pre-Markets Flat Again Ahead of Fed Report Tomorrow

by Mark Vickery

Market participants not look hungry to act until it understands more about the Fed's thinking.

Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Merck (MRK) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of 5.56% and 1.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Market Awaits JOLTS Numbers Due Tuesday

by Zacks Equity Research

Market Awaits JOLTS Numbers Due Tuesday.

Mark Vickery headshot

Big Numbers Ahead: Q2 Earnings, Fed Meeting, Jobs Week

by Mark Vickery

Jobs Week, Fed Week and the busiest week of Q2 earnings so far await us.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News

by Kinjel Shah

AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.

Sundeep Ganoria headshot

Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Sundeep Ganoria

Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.

Countdown to Merck (MRK) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View

by Zacks Equity Research

AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.

AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 3.11% and 2.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $125.92 in the latest trading session, marking a +1.24% move from the prior day.

Sweta Killa headshot

What Lies in Store for Healthcare ETFs in Q2 Earnings?

by Sweta Killa

The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.

Kinjel Shah headshot

Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?

by Kinjel Shah

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.

Merck (MRK) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

Merck (MRK) closed at $125.69 in the latest trading session, marking a -0.06% move from the prior day.